Aimei Health Technology Co Ltd (AFJK) is not a strong buy for a beginner, long-term investor at this time. The technical indicators suggest the stock is oversold, but there are no clear positive catalysts, recent news, or strong financial performance to support a buy decision. Additionally, the lack of trading signals and weak financial results further reduce its attractiveness.

Technical Analysis

The stock is oversold with an RSI of 19.305, indicating potential for a rebound. However, the MACD histogram is negative (-1.722), showing bearish momentum. Moving averages are converging, suggesting indecision in the market. Key support levels are at S1: 33.445 and S2: 28.958, while the stock is trading below the pivot level of 40.707.

Positive Catalysts

The stock is oversold, which may present a short-term rebound opportunity.

Neutral/Negative Catalysts

No AI Stock Picker or SwingMax signals. Congress trading data is unavailable.

Financial Performance

In Q3 2025, revenue remained flat at 0 (0% YoY growth). Net income dropped significantly by 52.65% YoY to 352,019, and EPS declined by 25% YoY to 0.06. Gross margin also showed no growth.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No data available for analyst ratings or price target changes.

Analyst Rating

Wall Street analysts forecast AFJK stock price to rise

Buy

Hold

Sell

Current: 32.310

Low

Averages

High